These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 34406410

  • 1. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C, Cusi K, Kadiyala S.
    J Clin Endocrinol Metab; 2022 Jan 01; 107(1):29-38. PubMed ID: 34406410
    [Abstract] [Full Text] [Related]

  • 2. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
    Goldenberg RM, Gilbert JD, Manjoo P, Pedersen SD, Woo VC, Lovshin JA.
    Obes Rev; 2024 Mar 01; 25(3):e13663. PubMed ID: 37968541
    [Abstract] [Full Text] [Related]

  • 3. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L, Li J, Zeng H, Liu J.
    Prim Care Diabetes; 2024 Jun 01; 18(3):268-276. PubMed ID: 38555202
    [Abstract] [Full Text] [Related]

  • 4. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF, Harrison SA, Sanyal AJ.
    Diabetes Obes Metab; 2024 Jun 01; 26(6):2001-2016. PubMed ID: 38511418
    [Abstract] [Full Text] [Related]

  • 5. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS, Marshman E, Noureddin M.
    Aliment Pharmacol Ther; 2022 Apr 01; 55(8):944-959. PubMed ID: 35266164
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
    Lee HA, Kim HY.
    Int J Mol Sci; 2023 May 26; 24(11):. PubMed ID: 37298276
    [Abstract] [Full Text] [Related]

  • 7. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
    Tsiampali C, Papaioannidou P, Goulas A, Polyzos SA.
    Expert Rev Clin Pharmacol; 2023 May 26; 16(11):1063-1072. PubMed ID: 37864548
    [Abstract] [Full Text] [Related]

  • 8. GLP-1 receptor agonists in NAFLD.
    Petit JM, Vergès B.
    Diabetes Metab; 2017 Apr 26; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [Abstract] [Full Text] [Related]

  • 9. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA, Guirguis E, Thornby KA.
    Ann Pharmacother; 2021 Jan 26; 55(1):65-79. PubMed ID: 32571083
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N.
    Clin Res Hepatol Gastroenterol; 2017 Jun 26; 41(3):284-295. PubMed ID: 28065744
    [Abstract] [Full Text] [Related]

  • 11. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Jun 26; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 12. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
    Belfort-DeAguiar R, Lomonaco R, Cusi K.
    J Clin Endocrinol Metab; 2023 Jan 17; 108(2):483-495. PubMed ID: 36305273
    [Abstract] [Full Text] [Related]

  • 13. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P, Rezaei S, Jalali M, Ashourpour M, Ahmadipour A, Keshavarz P, Akbari H.
    Eur J Pharmacol; 2021 Feb 15; 893():173823. PubMed ID: 33352183
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, Mantzoros CS.
    J Cardiovasc Pharmacol Ther; 2022 Feb 15; 27():10742484221146371. PubMed ID: 36546652
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y, Xu J, Zhang D, Mu X, Shi Y, Chen S, Wu Z, Li S.
    Front Endocrinol (Lausanne); 2021 Feb 15; 12():769069. PubMed ID: 34956080
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y, He H, Li S, Yang L, Wang X, Liu Z, An Z.
    Front Endocrinol (Lausanne); 2020 Feb 15; 11():622589. PubMed ID: 33664710
    [Abstract] [Full Text] [Related]

  • 17. Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.
    Chang KC, Kuo FC, Yang CY, Yang CT, Ou HT, Kuo S.
    Cardiovasc Diabetol; 2024 Oct 17; 23(1):367. PubMed ID: 39420429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun 17; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 20. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y, Xu YN, Ye CY, Feng WB, Zhou QT, Yang DH, Wang MW.
    Acta Pharmacol Sin; 2022 May 17; 43(5):1156-1166. PubMed ID: 34934197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.